Evaluating only Keros Therapeutics’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Competition.
Key Events Timeline
FOUNDING
Keros Therapeutics founded in Cambridge, MA to exploit TGF-beta biology in anemia and musculoskeletal disease.
FUNDING
Nasdaq IPO raises $101M; elritercept (KER-050) enters Phase 2 for MDS and myelofibrosis-related anemia.
Keros terminates elritercept, halts all clinical programs, retains $60M to pursue strategic alternatives with no pipeline.
Full Analysis
Free · no account needed
Documented cause
Keros Therapeutics, a TGF-beta superfamily-focused biotech, collapsed in September 2024 after its lead drug elritercept for myelodysplastic syndromes failed Phase 2 objectives. CEO John Quisel announced the company would explore strategic alternatives with $60M cash remaining after spending $280M total. The program was terminated after interim data at 16 weeks showed inadequate transfusion independence rates compared to luspatercept, Merck's approved competitor already dominating the market.
Lesson
“Entering a space with an approved competitor requires a clearly differentiated efficacy or safety profile from day one.”